Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
about
Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo.Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureusIn vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.Newer developments in the treatment of Gram-positive infections.Diet-Induced Obesity Does Not Alter Tigecycline Treatment Efficacy in Murine Lyme Disease.Treatment of infection caused by Borrelia burgdorferi sensu lato.Antibiotic dosing in critically ill patients with acute kidney injury.Protein binding: do we ever learn?PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.Rifampicin-containing combinations are superior to combinations of vancomycin, linezolid and daptomycin against Staphylococcus aureus biofilm infection in vivo and in vitro.Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.Tigecycline displays in vivo bactericidal activity against extended-spectrum-β-lactamase-producing Enterobacteriaceae after 72-hour exposure period.
P2860
Q34309522-13535E60-1A2E-4FB2-8C8C-E07D0629C3CBQ37120165-D1205237-B3B1-4732-83D8-BD6B11444F86Q37247619-58759DFC-A4DB-4D77-9B8C-E7742AAAD506Q37247732-81B8F896-5080-4F24-A7E5-48346CA8B851Q37450779-766DEB25-8867-4A3C-BB7E-B14C67FF0253Q37636151-437EF8AF-691D-43E5-93F1-891CF7D5576BQ37662663-452101CC-B00A-41CF-9EEE-84F716A1E641Q37845853-A70E3153-0A81-47E2-ABB0-23F85E2BC6CCQ37846092-55416F57-3BE1-4A68-90BB-97F84D014060Q37871252-645BB97D-8F14-467C-BF18-51EBF1169BAFQ38869564-A05EAB0A-E6CC-4A73-BDE3-4F9CD3C73BCEQ40334499-5B11D86C-B852-47AF-B0A7-57B850F29BEAQ40732100-3E4D59CA-5F68-46E6-B98B-6402C8B885E4Q41890029-5EA175E7-FD89-4AD6-A010-8A9B3BD17B62Q42529569-73B2E1E6-5A08-4097-BB98-9344DAD47570
P2860
Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacodynamics of tigecyclin ...... lates in a murine thigh model.
@en
Pharmacodynamics of tigecyclin ...... lates in a murine thigh model.
@nl
type
label
Pharmacodynamics of tigecyclin ...... lates in a murine thigh model.
@en
Pharmacodynamics of tigecyclin ...... lates in a murine thigh model.
@nl
prefLabel
Pharmacodynamics of tigecyclin ...... lates in a murine thigh model.
@en
Pharmacodynamics of tigecyclin ...... lates in a murine thigh model.
@nl
P2093
P2860
P356
P1476
Pharmacodynamics of tigecyclin ...... lates in a murine thigh model.
@en
P2093
David P Nicolau
Jared L Crandon
Mary Anne Banevicius
P2860
P304
P356
10.1128/AAC.00647-08
P407
P577
2008-12-29T00:00:00Z